Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $22.25

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.25.

A number of equities analysts have recently weighed in on the company. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. HC Wainwright downgraded shares of Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, January 22nd. BTIG Research reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Thursday, January 11th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Friday, January 12th.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of large investors have recently bought and sold shares of ACRS. SG Americas Securities LLC lifted its holdings in shares of Aclaris Therapeutics by 20.1% during the 3rd quarter. SG Americas Securities LLC now owns 151,704 shares of the biotechnology company’s stock worth $1,039,000 after acquiring an additional 25,357 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Aclaris Therapeutics by 42.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,317 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 6,074 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Aclaris Therapeutics by 7.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 687,135 shares of the biotechnology company’s stock valued at $4,707,000 after purchasing an additional 50,306 shares in the last quarter. Barclays PLC increased its stake in shares of Aclaris Therapeutics by 174.2% in the 3rd quarter. Barclays PLC now owns 234,150 shares of the biotechnology company’s stock valued at $1,603,000 after purchasing an additional 148,761 shares during the last quarter. Finally, Lord Abbett & CO. LLC raised its holdings in shares of Aclaris Therapeutics by 14.0% during the 3rd quarter. Lord Abbett & CO. LLC now owns 453,954 shares of the biotechnology company’s stock worth $3,110,000 after buying an additional 55,602 shares in the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Trading Up 0.4 %

NASDAQ ACRS opened at $1.23 on Friday. The firm’s fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.53. Aclaris Therapeutics has a 1 year low of $0.59 and a 1 year high of $11.12. The firm has a market capitalization of $87.30 million, a P/E ratio of -0.96 and a beta of 0.23.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. The company had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $3.96 million. On average, research analysts anticipate that Aclaris Therapeutics will post -0.98 EPS for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.